Cigarette smoking cessation, duration of smoking abstinence, and head and neck squamous cell carcinoma prognosis

Abstract

AbstractBackgroundTobacco use is a major risk factor for developing head and neck squamous cell carcinoma (HNSCC). However, the prognostic associations with smoking cessation are limited. The authors assessed whether smoking cessation and increased duration of abstinence were associated with improved overall (OS) and HNSCC‐specific survival.MethodsClinicodemographic and smoking data from patients with HNSCC at Princess Margaret Cancer Center (2006–2019) were prospectively collected. Multivariable Cox and Fine and Gray competing‐risk models were used to assess the impact of smoking cessation and duration of abstinence on overall mortality and HNSCC‐specific/noncancer mortality, respectively.ResultsAmong 2482 patients who had HNSCC, former smokers (adjusted hazard ratio [aHR], 0.71; 95% CI, 0.58–0.87; p = .001; N = 841) had a reduced risk of overall mortality compared with current smokers (N = 931). Compared with current smokers, former smokers who quit >10 years before diagnosis (long‐term abstinence; n = 615) had the most improved OS (aHR, 0.72; 95% CI, 0.56–0.93; p = .001). The 5‐year actuarial rates of HNSCC‐specific and noncancer deaths were 16.8% and 9.4%, respectively. Former smokers (aHR, 0.71; 95% CI, 0.54–0.95; p = .019) had reduced HNSCC‐specific mortality compared with current smokers, but there was no difference in noncancer mortality. Abstinence for >10 years was associated with decreased HNSCC‐specific death compared with current smoking (aHR, 0.64; 95% CI, 0.46–0.91; p = .012). Smoking cessation with a longer duration of quitting was significantly associated with reduced overall and HNSCC‐specific mortality in patients who received primary radiation.ConclusionsSmoking cessation before the time of diagnosis reduced overall mortality and cancer‐specific mortality among patients with HNSCC, but no difference was observed in noncancer mortality. Long‐term abstinence (>10 pack‐years) had a significant OS and HNSCC‐specific survival benefit.